We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for AEterna (AEZS) This Earnings Season?
Read MoreHide Full Article
Investors’ focus will be on the progress of AEterna Zentaris Inc.’s (AEZS - Free Report) Macrilen in Europe when the company reports first-quarter 2019 results.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and missed the same once with the average positive surprise being 273.38%.
Shares of AEterna have gained 23.1% so far this year against the industry‘s rise of 4%.
In the last reported quarter, AEterna delivered a negative earnings surprise of 63.16%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
AEterna is focused on expanding the reach of its sole marketed product, Macrilen, through licensing. Macrilen is the first and only FDA-approved oral test for the diagnosis of adult growth hormone deficiency (“AGHD”). AEterna earns royalties on the sales of the product, which is currently marketed by Novo Nordisk (NVO - Free Report) in the United States and Canada.
In January, Macrilen was approved for a similar indication in Europe. The company may provide update on launch initiatives in Europe on its first-quarter earnings call. We note that the performance of Macrilen has not been encouraging since its launch in 2017 in the United States.
We note that in March, a process to review various strategic options available to put AEterna on growth path was initiated. A global investment bank specializing in life sciences, Torreya, is acting as financial advisor to the company. The company may also provide updates on the options available.
Operating expenses in the first quarter are likely to be lower due to decreased research and development activities as well as lower selling expenses due to out-licensing of commercialization of Macrilen.
Earnings Whispers
Our proven model does not conclusively show that AEterna is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: AEterna’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at earnings of 4 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although AEterna’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) has an Earnings ESP of +255.56% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 9.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
What's in the Cards for AEterna (AEZS) This Earnings Season?
Investors’ focus will be on the progress of AEterna Zentaris Inc.’s (AEZS - Free Report) Macrilen in Europe when the company reports first-quarter 2019 results.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and missed the same once with the average positive surprise being 273.38%.
Shares of AEterna have gained 23.1% so far this year against the industry‘s rise of 4%.
In the last reported quarter, AEterna delivered a negative earnings surprise of 63.16%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
AEterna is focused on expanding the reach of its sole marketed product, Macrilen, through licensing. Macrilen is the first and only FDA-approved oral test for the diagnosis of adult growth hormone deficiency (“AGHD”). AEterna earns royalties on the sales of the product, which is currently marketed by Novo Nordisk (NVO - Free Report) in the United States and Canada.
In January, Macrilen was approved for a similar indication in Europe. The company may provide update on launch initiatives in Europe on its first-quarter earnings call. We note that the performance of Macrilen has not been encouraging since its launch in 2017 in the United States.
We note that in March, a process to review various strategic options available to put AEterna on growth path was initiated. A global investment bank specializing in life sciences, Torreya, is acting as financial advisor to the company. The company may also provide updates on the options available.
Operating expenses in the first quarter are likely to be lower due to decreased research and development activities as well as lower selling expenses due to out-licensing of commercialization of Macrilen.
Earnings Whispers
Our proven model does not conclusively show that AEterna is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: AEterna’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at earnings of 4 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although AEterna’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
AEterna Zentaris Inc. Price and Consensus
AEterna Zentaris Inc. Price and Consensus | AEterna Zentaris Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Horizon Pharma has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8. You can see the complete list of today’s Zacks #1 Rank stocks here.
Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) has an Earnings ESP of +255.56% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 9.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>